Patents by Inventor Klaus Peseke

Klaus Peseke has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • SUBSTITUTED HYDROXYACETOPHENONE DERIVATIVES
    Publication number: 20090234023
    Abstract: The present invention relates to substituted hydroxyacetophenone derivatives having antiproliferative and antimicrobial properties, to pharmaceutical compositions containing them, as well as to a method of preparing them. Moreover, the hydroxyacetophenone derivatives according to the invention can serve as organic intermediates for the preparation of biologically active compounds.
    Type: Application
    Filed: July 6, 2005
    Publication date: September 17, 2009
    Applicant: Riemser Arzneimittel AG
    Inventors: Jose Agustin Quincoces Suarez, Klaus Peseke, Ernesto Estrada Roger
  • Method for the preparation of 1,5-bis(4-hydroxy-3-metoxy-phenyl)-penta-1,4-dien-3-one and derivatives with antitumoral properties
    Patent number: 7432401
    Abstract: This patent of invention reports the method for the preparation of 1,5-bis(4-hydroxy-3-methoxyphenyl)-penta-1,4-dien-3-one and derivatives with antitumoral properties: the sample denominated 37 compound was obtained with high yield and purity with ultrasonic technique presenting cytostatic activity (growth inhibition) in the concentrations evaluated and cytotoxic activity (cellular death) from the concentration of 0.25 mg/mL against nine different types of human cancer cell lines. This compound has a LD50, equals to 8.54 g/Kg. That means this product can be considered itself as practically nontoxic. Doxorubicin, anticarcinogen medicine used as reference in all these tests, is a product extremely toxic (LD50 of 20 mg/Kg) and it does not inhibit the growth of Mama NCI-ADR cell line (the one that expresses the phenotype of resistance against multiple drugs), therefore, out product presented a strong cytostatic activity.
    Type: Grant
    Filed: November 28, 2003
    Date of Patent: October 7, 2008
    Assignee: Fundação de Amparo a Pesquisa Do Estado de São Paulo
    Inventors: José Agustin Quincoces Suárez, Klaus Peseke, Markus Kordian, João Ernesto Carvalho, Luciana Konecny Kohn, Márcia Aparecida Antônio, Heloiza Brunhari
  • New method for the preparation of 1,5-bis(4-hydroxy-3-metoxy-phenyl)-penta-1,4-dien-3-one and derivatives with antitumoral properties
    Publication number: 20060128997
    Abstract: This patent of invention reports the method for the preparation of 1,5-bis(4-hydroxy-3-methoxyphenyl)-penta-1,4-dien-3-one and derivatives with antitumoral properties: the sample denominated 37 compound was obtained with high yield and purity with ultrasonic technique presenting cytostatic activity (growth inhibition) in the concentrations evaluated and cytotoxic activity (cellular death) from the concentration of 0.25 mg/mL against nine different types of human cancer cell lines. This compound has a LD50, equals to 8.54 g/Kg. That means this product can be considered itself as practically nontoxic. Doxorubicin, anticarcinogen medicine used as reference in all these tests, is a product extremely toxic (LD50 of 20 mg/Kg) and it does not inhibit the growth of Mama NCI-ADR cell line (the one that expresses the phenotype of resistance against multiple drugs), therefore our product presented a strong cytostatic activity.
    Type: Application
    Filed: November 28, 2003
    Publication date: June 15, 2006
    Inventors: Jose Suarez, Klaus Peseke, Markus Kordian, Joao Carvalho, Luciana Kohn, Marcia Antonio, Heloiza Brunhari